Skip to content
DataLookout
Menu

NCT07934745

Radiotherapy Plus Putelimab and Vibostolimab for Advanced Anal Squamous Cell Carcinoma

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Objective Response Rate (ORR)
Timeframe: From enrolment until first documented disease progression, death, subsequent anti-cancer therapy, or loss to follow-up,assessed up to 24 months. Responses require confirmation ≥4 weeks after first documentation.

Secondary (3)

3-year Overall survival rate
3-year Disease-Free Survival (DFS) Rate
Adverse Events (AEs)

Arms and interventions

treatmentExperimental

Radiotherapy is delivered to recurrent or metastatic lesions. Thereafter, the PD-1 inhibitor putelimab in combination with the EGFR-targeted ADC vibostolimab is administered once every 3 weeks until disease progression or intolerable toxicity.

Drugs: putelimab combined with vibostolimab